Ziegler Jl
About
In The Last Decade
Ziegler Jl
24 papers receiving 385 citations
Peers
Comparison fields: 5 of 53
- Oncology 225
- Pathology and Forensic Medicine 173
- Hematology 129
- Neurology 76
- Genetics 70
Countries citing papers authored by Ziegler Jl
This map shows the geographic impact of Ziegler Jl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ziegler Jl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ziegler Jl more than expected).
Fields of papers citing papers by Ziegler Jl
This network shows the impact of papers produced by Ziegler Jl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ziegler Jl. The network helps show where Ziegler Jl may publish in the future.
Co-authorship network of co-authors of Ziegler Jl
This figure shows the co-authorship network connecting the top 25 collaborators of Ziegler Jl. A scholar is included among the top collaborators of Ziegler Jl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ziegler Jl. Ziegler Jl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | The value of a clinical definition for epidemic KS in predicting HIV seropositivity in Africa. | 6 |
| 2 | Lymphomas and other neoplasms associated with AIDS. | 5 |
| 3 | Phase II chemotherapy trials of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder. | 4 |
| 4 | Ifosfamide treatment of pancreatic cancer. | 19 |
| 5 | Phase II trial of cis-dichlorodiammineplatinum(II) in cancer of the bilharzial bladder. | 1 |
| 6 | 40 | |
| 7 | Phase II trial of adriamycin in carcinoma of the bilharzial bladder. | 3 |
| 8 | Combined modality treatment of Burkitt's lymphoma. | 21 |
| 9 | Sequential combination chemotherapy (containing high-dose cyclophosphamide) for metastic osteogenic sarcoma. | 4 |
| 10 | 194 | |
| 11 | Burkitt's lymphoma--a model for intensive chemotherapy. | 21 |
| 12 | Spontaneous remission in Burkitt's lymphoma. | 34 |
| 13 | Malarial antibodies in tropical splenomegaly syndrome in Uganda. | 6 |
| 14 | BCG immunotherapy in Burkitt's lymphoma: preliminary results of a randomized clinical trial. | 12 |
| 15 | [Burkitt's lymphoma]. | 6 |
| 16 | Current concepts. Recent research in Burkitt's lymphoma. | 2 |
| 17 | Treatment of histiocytic lymphoma in Uganda adults. | 2 |
| 18 | Clinical trials of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) given intravenously in the treatment of malignant melanoma in Uganda. | 3 |
| 19 | Acute necrotizing encephalitis in a patient with Hodgkin's disease. A case report. | 2 |
| 20 | Malignant melanoma in Uganda. | 26 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.